Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders.
We investigated the plasma levels of VEGF and FGF-2, important factors for regulation of neuroplasticity such as neurogenesis, in patients in remission from major depressive disorders (MDD). The plasma VEGF levels were significantly higher in the MDD patients than in the matched control subjects, while no significant difference in plasma FGF-2 levels was found. In particular, the MDD patients with family history of psychiatric disorders, but not patients without such a family history, showed significantly higher values of plasma VEGF than the controls. Although this is a preliminary study, altered VEGF levels might be involved in the pathophysiology of MDD.
Takebayashi
M
M
Department of Psychiatry, National Hospital Organization (NHO) Kure Medical Center, 3-1 Aoyama, Kure 737-0023, Japan. mtakebayashi@kure-nh.go.jp
Hashimoto
R
R
Hisaoka
K
K
Tsuchioka
M
M
Kunugi
H
H
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D003865:Major Depressive Disorder / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2